PARP is a multifunctional protein that can aect genome stability, transcription control, telomere length and cell death. Recently we have reported that PARP binds to and enhances B-MYB transactivating potential. B-MYB is a potentially oncogenic transcription factor involved in mammalian cell proliferation, survival and dierentiation. B-MYB gene expression is growth regulated and B-MYB protein is phosphorylated during S phase by cyclin A or E/cdk2 kinase, resulting in augmented transactivating potential. Here we show that PARP induces phosphorylation of B-MYB protein at cdk2 phosphorylation sites, since a B-MYB protein with mutated cdk2 phosphorylation sites is refractory to PARP-induced phosphorylation and co-activation in mammalian cells. We propose that PARP functions as a B-MYB co-factor by promoting cyclin/cdk2-dependent B-MYB phosphorylation. These results highlight a novel role for PARP as a factor that integrates cyclindependent kinases signaling with gene transcription. Oncogene (2001) 20, 8167 ± 8174.
Introduction
Many cellular processes depend on the concerted activity of molecules that contribute to the coordinated expression of genes. Transcription factors are the direct regulators of gene activity, through the recognition and engagement of cis-regulatory sequences. Transcription factors are regulated at the post-translational level by several mechanisms, including phosphorylation, degradation and interaction with co-activators. Thesè controllers of the controller' allow timely execution and ®ne tuning of gene transcription. Moreover, coactivators often connect transcription factors with the signaling pathways, allowing swift modulation of gene expression in response to changing physiologic requirements. In a previous report we demonstrated that PARP interacts with and co-activates the B-MYB oncoprotein . PARP is a chromatin protein involved in cellular processes such as DNA replication, DNA repair, control of telomere length and genome stability (Damours et al., 1999) . PARP role in transcription control is emerging as a major aspect of the biological functions ascribed to PARP, mainly through direct interaction with transcription factors. Although PARP may repress transcription by adding units of poly(ADP-ribose) to target protein substrates, it has also been shown that PARP can enhance the activity of the bound transcription factors through mechanisms of co-activation that are not yet understood. For example, PARP interacts with and enhances the transactivating activity of AP-2 (Kannan et al., 1999) , and increases transcription of the PAX-6 gene (Plaza et al., 1999) . PARP co-activates B-MYB in the absence of its polymerase activity, since PARP enzyme-dead variants are still able to synergize with B-MYB . This is not surprising in the light of previous reports showing the suppressive eects of poly (ADP-ribose) units bound to transcription factors. In this regard, it has been shown that PARP suppresses nuclear hormone signaling (Miyamoto et al., 1999) and that p53 binding to DNA is inhibited by direct interaction of p53 domains with polymers of poly (ADP) ribose (Malanga et al., 1998) .
B-MYB is a transcription factor belonging to the myb family whose prototype member, c-MYB, is the cellular homologue of the oncogene carried by the E26 and AMV retroviruses (Graf, 1992; Nomura et al., 1988) . c-MYB and A-MYB play important roles in tissue-speci®c cellular processes while B-MYB is thought to have a general role in cellular proliferation and dierentiation (Saville and Watson, 1998; .
B-MYB gene expression is growth regulated and peaks at the G1/S transition of the cell cycle (Reiss et al., 1991; Lam et al., 1992) . Growth regulation is achieved through an E2F site which down-modulates B-MYB expression during the G0/G1 phase, probably through recruitment of p130/p107 suppressor proteins (Lam and Watson, 1993; Hurford et al., 1997; Zwicker et al., 1996) . Endogenous B-MYB protein is phosphorylated at the onset of DNA synthesis by cyclin A/ cdk2 kinase (Robinson et al., 1996) . Consistent with this ®nding, several laboratories have demonstrated that B-MYB transactivating potential correlates with phosphorylation induced by the cyclinA/cdk2 kinase complex (Ansieau et al., 1997; Lane et al., 1997; Sala et al., 1997; Ziebold et al., 1997; Johnson et al., 1999) . Similarly to phosphorylation, truncation of the carboxyl-terminus of B-MYB protein results in activation of B-MYB transactivating ability (Lane et al., 1997; Ziebold et al., 1997) . This has lead to the hypothesis that B-MYB function is negatively aected by intramolecular interactions and/or by homodimerization (Ansieau et al., 1997; Kim et al., 1999) . The cell cycle-dependent regulation of B-MYB mRNA and protein levels suggests that B-MYB function is required mainly during the S phase. This hypothesis is corroborated by experiments showing that ectopic B-MYB expression perturbs the human cell cycle only at the onset of S phase, concurrent with cell cycle oscillation of mitotic cyclins (Sala et al., 1996) . In keeping with these data, B-MYB greatly stimulates S phase in the presence of ectopically expressed cyclin A or E (Lane et al., 1997; Sala et al., 1997) . Ablation of endogenous levels of B-MYB protein by means of the antisense techniques causes block of cellular proliferation of normal and transformed cell lines, suggesting a function in cell cycle progression and/or in survival mechanisms (Arsura et al., 1992; Sala and Calabretta, 1992; Lin et al., 1994; RaschellaÂ et al., 1995) . Consistent with the antisense data, B-MYB-null mice die in utero at a very early stage of development due to impaired inner cell mass formation (Tanaka et al., 1999) . Given the potentially wide implications of aberrant regulation of B-MYB activity in cellular processes, in this study we have attempted to explore the mechanisms by which PARP modulates B-MYB transactivating potential.
Results

PARP co-activation depends on the integrity of cyclin A/cdk2 phosphorylation sites on B-MYB protein
We have shown previously that PARP enhances B-MYB transactivating potential . B-MYB transactivation is also increased by expression of cyclin/cdk2 kinases that phosphorylate B-MYB in the carboxyl-terminus (Ansieau et al., 1997; Lane et al., 1997; Sala et al., 1997; Ziebold et al., 1997; Johnson et al., 1999) . To assess the possibility of cross-talk between the PARP and cyclin pathways, SAOS2 cells were transiently transfected with a luciferase gene driven by a MYBresponsive promoter, and with FLAG-tagged wild-type B-MYB or a B-MYB mutant with 10 amino acid substitutions at cyclin A/cdk2 phosphorylation sites. It was shown in an earlier study that the B-MYB 10mut is refractory to cyclinA/cdk2 activation in transient transfection assays (Johnson et al., 1999) . Notably, PARP was not able to co-activate mutant B-MYB, suggesting that its co-activating ability depends on the integrity of cyclin A/ cdk2 phosphorylation sites (Figure 1a,b) . Correct expression of the dierent constructs was monitored by Western blotting (Figure 1c) . A dose response experiment suggests that co-activation is reduced in the presence of high levels of transfected PARP (Figure 2a,b) . We next assessed whether B-MYB transactivating ability was aected in cells with a disrupted PARP gene. Wild-type or mutant 10 B-MYB were both able to transactivate the reporter gene but only wild-type B-MYB was signi®cantly co-activated by PARP (Figure 3 ). Residual co-activation evidenced by co-transfecting cells with 1 mg of PARP and mutant B-MYB protein could be due to further phosphorylation sites which were unaected. Interestingly, cyclin A was unable to behave as a co-activator of wild-type B-MYB in this setting, suggesting that endogenous levels of PARP are required for its activity (Figure 3 , left histogram). PARP interacts with the B-MYB DNA-binding domain , whereas the mutated amino (c) Expression levels of the products encoded by the transfected plasmids were compared to that of the endogenous genes by western blot analysis. Beta actin protein levels were monitored to assess equal loading of the lanes acids are located at the carboxyl-terminus of the B-MYB molecule, rendering unlikely the hypothesis that the loss of the synergistic eect is due to loss of physical interaction. However, cells were transfected with mutant or wild-type B-MYB vectors with or without PARP. Coimmunoprecipitation experiments showed that mutation of the 10 amino acids does not signi®cantly aect the PARP/B-MYB interaction (Figure 4 ).
PARP induces B-MYB phosphorylation
Western blot analysis revealed that PARP transfection induced a slower migrating B-MYB band which comigrated with that induced by cyclin A (Figure 5a ). Since cyclin A transfection results in the appearance of phosphorylated bands with slower electrophoretic mobility (Ansieau et al., 1997; Lane et al., 1997; Sala et al., 1997; Ziebold et al., 1997; Johnson et al., 1999) , we hypothesized that PARP may directly aect the phosphorylation status of B-MYB protein. To test this hypothesis, nuclear extracts from 293 cells transfected with tagged B-MYB were mixed with nuclear extracts from PARP-or cyclin A-transfected cells in the presence of 32 P-gATP ( Figure 5b , left panel). As expected, B-MYB protein immunoprecipitated with a FLAG antibody was phosphorylated in the presence of nuclear extracts containing cyclin A (Figure 5b ). Extracts from PARP-transfected cells, but not control extracts, also induced B-MYB phosphorylation (Figure 5b) . It should be noted that PARP, consistent with the luciferase assay, did not promote phosphorylation of the mutant B-MYB, suggesting that PARPinduced phosphorylation is dependent on cyclin/cdk2 For the in vitro kinase assay, 293 cells were transiently transfected with FLAG-tagged B-MYB or B-MYB mutant 10 and nuclear lysates were subjected to immunoprecipitation with FLAG antibody after the kinase reaction in the presence of PARP or cyclin A or control lysates (left panel). Immunocomplexes were blotted onto nitrocellulose membrane and exposed to x-ray ®lm to detect phosphorylated B-MYB (top). Equal amount of immunoprecipitated material from the dierent transfectants were analysed by Western blotting with a B-MYB antibody (bottom). Histone H1 was subjected to the in vitro kinase assay, as described in the Materials and methods section. The assay was repeated twice with similar results (right panel). (c) Nuclear lysates of 293 cells transfected with empty, PARP or cyclin A expression vectors were subjected to Western blot analysis with the appropriate antibodies to monitor correct expression of the dierent transgenes before the in vitro kinase assay. The blot was probed ®rst with the PARP antibody and, after stripping, with the cyclin A antibody Overexpression of PARP and cyclin A proteins in the transfected cell nuclear extracts was monitored by Western blot analysis (Figure 5c ). CIS-dominant-negative effect of the B-MYB DNA-binding domain PARP binds directly to the B-MYB DNA-binding domain region , whereas cdk2 phosphorylation sites are concentrated mainly in the carboxyl-terminus of B-MYB (Johnson et al., 1999) . We hypothesized that PARP may render B-MYB a better substrate for endogenous cyclin-dependent kinases upon binding to the B-MYB amino-terminus. To test this hypothesis we did not elect to mutagenize the two proteins to disrupt the binding, since introduction of mutations may aect other biological functions with confounding eects. Instead, immunoprecipitated Flag-B-MYB protein was subjected to the in vitro kinase assay in the presence of GST fused to the B-MYB DNAbinding domain. We predicted that an excess of the B-MYB-amino terminus (GST-N-B-MYB) should inhibit B-MYB phosphorylation in cis-but not in trans-. In other words, if PARP eect is dictated by its binding to B-MYB an excess of the B-MYB amino-terminus should titrate PARP and phosphorylation of full-length B-MYB should not be observed (cis-eect). In contrast, should a physical association not be required, the fusion protein should not behave as an inhibitor. Indeed, GST-N-B-MYB, but not GST alone, inhibited PARP-induced phosphorylation of the tagged B-MYB protein ( Figure  6a) , consistent with the hypothesis that PARP facilitates the activity of endogenous cyclin-dependent kinases. The inhibitory eect of GST-N-B-MYB was not caused by depletion of the kinase, since GST-N-B-MYB was able to absorb PARP, but not cyclin A or cdk2 in pull-down experiments (Figure 6b) .
B-MYB is not poly(ADP-ribosyl)ated by PARP
The hypothesis that B-MYB phosphorylation could be facilitated by PARP-dependent poly(ADP-rybosyl)ation of the B-MYB protein was veri®ed. To this end, 293T cells were co-transfected with PARP and B-MYB expression vectors. Cell lysates were immunoprecipitated with B-MYB antibody and protein poly(ADP-ribosyl)-ation was monitored by Western blotting with a monoclonal antibody that recognizes poly(ADP-ribose) units. A protein lysate from serum starved 293 cells, used as a positive control, was strongly stained by the antibody (Figure 7a, lane 1, upper panel) . In contrast, immunoprecipitated material from a rabbit control antibody ( Figure 7a, lanes 2,3,4, upper panel) or Bmyb-speci®c antibody (Figure 7a , lanes 5,6,7, upper panel) did not show reactivity for the poly (ADP-ribose) antibody, even in the presence of exogenous PARP. Western blotting with the B-MYB antibody con®rmed that B-MYB protein was present in the immunoprecipitated material (Figure 7a, lanes 6,7) . It could be argued that poly(ADP-ribosyl)ation may negatively aect immunoprecipitation of the B-MYB protein. To address this point, we transiently co-transfected 293 cells with PARP and B-MYB and monitored poly (ADP-ribosyl)-ation of protein cell lysates by Western blot analysis. Staining of a 110 ± 120 kD protein by the poly ADP ribose antibody was signi®cantly increased after trans- . After several washings the resin was dissolved in sample buer, run in a SDS gel and blotted onto nitrocellulose. Cellular PARP, but not cyclin A or cdk2, was absorbed by the resin containing GST-N-BMYB. Expression levels of the dierent proteins in the nuclear lysate was assessed by Western blotting with the indicated antibodies after sequential stripping of the blot and it is shown in lane 3 fection of the PARP vector (Figure 7b left panel) . Notably, neither the pattern of B-MYB expression nor its molecular weight correlated with that of the poly-ADP-ribosylated protein suggesting that B-MYB is not a PARP substrate (Figure 7b, middle panel) . It is possible that the poly ADP-ribosylated protein is PARP itself, since it co-migrates with the 110 ± 120 kD poly-ADPribosylated protein (Figure 7b , right panel). Overall these results are consistent with previous data indicating that PARP polymerase activity is not involved in B-MYB coactivation Discussion In a previous report we have isolated proteins that bound to the B-MYB amino-terminus which may be involved in modulating its activity . One of the bound proteins was PARP, and we have shown that it can enhance B-MYB-dependent transactivation . Notably, PARP co-activates B-MYB in the absence of its polymerase activity, since PARP enzyme-dead variants are still eective . This suggests that events other than poly (ADP-ribosyl)ation are at the base of the synergistic eect. It has been reported that PARP co-activating function is associated with the relief of the self-inhibiting function of the transcription factor AP2 (Kannan et al., 1999) . It was proposed that B-MYB is a self-repressed molecule and some experimental evidence suggests that B-MYB phosphorylation by cyclin-cdk2 kinase could negatively modulate intra-and extra-molecular selfinteractions (Ansieau et al., 1997; Lane et al., 1997; Sala et al., 1997; Ziebold et al., 1997; Johnson et al., 1999 , Kim et al., 1999 . Since the PARP transcriptional eect is reminiscent of that which results from cyclin-dependent phosphorylation, in this study we set up experiments aimed at addressing the question of whether PARP is involved in B-MYB phosphorylation. Here we provide evidence that PARP co-activates B-MYB by enhancing its phosphorylation. A mutated B-MYB protein where the 10 major cyclin A/cdk2-phosphorylation sites were eliminated is partially refractory to cyclin-induced activation (Johnson et al., 1999) . We have used this mutant to show that phosphorylation is the key event underlying the PARP co-activating eect, since mutant B-MYB cannot synergize with PARP in transient transfection assays and it is not phosphorylated by nuclear extracts containing PARP (Figures 1 ± 3 and 5) . The hypothesis that PARP is an essential player in cylin A/cdk2 kinase-induced B-MYB phosphorylation is suggested by the ability of cyclin A to activate B-MYB transcriptional activity in dierent cell types ( Figure 1a and Ansieau et al., 1997; Lane et al., 1997; Sala et al., 1997; Ziebold et al., 1997; Johnson et al., 1999) but not in cells with a disrupted PARP gene (Figure 3a) . How does PARP induce B-MYB phosphorylation? One could hypothesize that PARP stimulates cdk2 activity in a manner similar to that of cyclins. However, this hypothesis is unlikely since PARP does not interact with cdk2 or stimulate phosphorylation of other cyclin/cdk2 substrates, such as histone H1 (Figure 5b and unpublished data). PARP stimulates B-MYB phosphorylation in cis-, suggested by the dominant-negative eect exerted by the B-MYB amino-terminus in the in vitro kinase assay (Figure 6 ). Since PARP polymerase activity is not involved in B-MYB co-activation Figure 7) , it is tempting to speculate that PARP induces phosphorylation of the bound B-MYB molecule by conformational changes that facilitate access of cellular cyclin A/cdk2 kinases.
PARP expression level may vary during dierent physiologic conditions. For instance, a transient increase of PARP is observed during dierentiation-linked DNA replication of 3T3-L1 preadipocytes (Simbulan-Rosenthal et al., 1996) , or during estrogen stimulation of mammary cancer cells (A Sala, unpublished observation). Antisense inhibition of PARP results in the G0/G1 block of 3T3-L1 cells, suggesting that PARP may play a regulatory role within the replicative apparatus (Simbulan-Rosenthal et al., 1996) . Here we propose that physiologic or aberrant regulation of PARP level within the cell may in¯uence gene transcription by altering transactivating properties of B-MYB and, perhaps, of other transcription factors. We have recently demonstrated in our laboratory that augmented survival properties of the LAN-5 neuroblastoma cell line transfected with a B-MYB transgene is due to transcriptional activation of the Apolipoprotein J (clusterin) gene . Increased B-MYB and ApoJ mRNA level is associated with advanced stages of neuroblastoma (RaschellaÁ et al., 1999, and unpublished data) , suggesting that B-MYB may promote the progression of human cancer through transactivation of downstream eector genes involved in cell survival. PARP level is augmented in lymphomas or in Ewing sarcoma (Menegazzi et al., 1999; Soldatenkov et al., 1999) . Accordingly, one could hypothesize that aberrant expression of PARP in tumors may favor disease progression by enhancing transactivation of B-MYB-target genes. The results presented in our study are of particular relevance in the light of recent observations suggesting that PARP de®ciency leads to de®cit of mitotic genes expression (Simbulan-Rosenthal et al., 2000) .
Materials and methods
Cell lines
The human osteosarcoma cell line SAOS and the human embryonic kidney cell line HEK 293 were obtained from ATCC. Both cell lines were maintained in Dulbecco's modi®ed Eagle's medium (GIBCO) supplemented with 15% fetal calf serum and 10% fetal calf serum, respectively. PARP7/7 ®broblasts, a kind gift from Dr Z Wang, were cultured in DMEM supplemented with 10% fetal calf serum.
Plasmids pCMV, pcDNA3-PARPwt, pcDNA3-cyclin A, pcDNA3-FLAG-B-MYB, pcDNA3-FLAG B-MYB 10 mut were all described Sala et al., 1997; Johnson et al., 1999) .
Transient transfections and nuclear extracts
HEK 293 (293T) cells were plated at the density of 50 000 cells/ cm 2 the day before transfection. Cells were transfected by standard calcium phosphate precipitation method. Nuclear extracts were obtained according to Dignam (Dignam et al., 1983) with few modi®cations. In brief, the cells were lysed in 500 ml of buer A (5% sucrose, 10 mM KOH ± HEPES, pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5% Nonidet P-400, 0.5 mM dithiothreitol) with protease inhibitors (Complete tm tablets; Boheringer) and centrifuged at 13 000 r.p.m. for 5 min at 48C. The supernatant was discarded and the nuclear pellet was incubated in buer B (20 mM KOH ± HEPES, 20% glycerol, 100 mM NaCl, 100 mM KCl, 0.5 mM dithiothreitol) for 10 min on ice in the presence of protease (Complete tm tablets, Boheringer) and phosphatase inhibitors (1 mM sodium vanadate, 10 mM sodium¯uoride, 25 mM b-glycerophosphate). Nuclear proteins were quanti®ed by the Bradford method following the manufacturer's instructions (Bio-Rad).
In vitro kinase assay 293 T-cells were transfected with the dierent B-MYB constructs and after 48 h nuclear extracts were prepared. Thirty mg of nuclear protein from B-MYB-transfected cells were mixed with 20 mg of nuclear proteins from 293 cells transfected with empty vector or CMV ± PARP or CMV ± cyclin A and incubated on ice for 30 min. The kinase reaction was carried out in 16reaction buer (20 mM Tris HCl, pH 7.5, 10 mM MgCl, 5 mM ATP, and 0.2 ml of g 32 P ATP 10 m Ci/ml, 6000 Ci/mmol; Amersham Pharmacia Biotech), in the presence of protease and phosphatase inhibitors, and incubating the mix for 20 min at 378C. FLAG-tagged B-MYB proteins were immunoprecipitated with anti-FLAG agarose-conjugated antibody (Sigma, St. Louis, USA) for 1 h at 48C in a buer containing 10 mM Tris-HCl, pH 7.2, 150 mM NaCl, 0.1% Nonidet P-40, 2 mM EDTA with protease and phosphatase inhibitor. After ®ve washes, samples were loaded onto a SDS-polyacrylamide gel. The gel was washed with TCA 5%, dried and exposed to autoradiography ®lm overnight at 7808C. For competition experiments, bacterially produced GST or GST-N-B-MYB fusion protein were added to the kinase mix. Histone H1 (Sigma, St. Louis, USA) was used as a substrate for kinase reactions by mixing 10 ng of it with 20 mg of nuclear extracts from 293 T-cells transfected with the dierent plasmids using same conditions described above. Lysates were dissolved in SDS-sample buer and run on a 12% SDS gel. At the end of the run, he gel was stained in Brilliant Blue Coomassie, dried and exposed to an X-ray ®lm to detect phosphorylated H1 protein.
Immunoprecipitation/Western blot 293 T-cells were transfected with the dierent constructs and lysed in 500 ml of lysis buer and immunoprecipitated with 20 ml of anti-FLAG antibody. Cells were lysed in isotonic buer (HEPES K-OH 20 mM pH 7.5, NaCl 150 mM, 1% NP-40, protease and phosphatase inhibitors) and immunoprecipitated with 1 mg of the indicated antibodies in IP buer (HEPES K-OH 20 mM pH 7.5, 150 mM NaCl, 0.5% NP-40, protease and phosphatase inhibitors). After six washes in IP buer, samples were run in a SDS-polyacrilammide gel and transferred to nitrocellulose. The nitrocellulose ®lter was blocked in PBS containing 5% dry milk and 0.1% Nonidet P40 and incubated with BM-2 B-MYB antibody (a kind gift of Dr Roger Watson) or a comercial B-MYB antibody (c-20, Santa Cruz, USA). Other antibodies used were PARP antibody (Biomol, USA) and anti-PAR (Chemicon, USA). After washes, ®lters were incubated with the appropriate secondary antibody labeled with horseradish-peroxidase, followed by incubation with chemiluminescence substrate (ECL, Amersham Pharmacia Biotech). Proteins were detected by exposing the nitrocellulose ®lter to autoradiographic ®lm.
Luciferase assay
SAOS-2 cells and PARP7/7 ®broblasts were plated in 6-well plates and transfected with the reporter construct pGL2-MIM1 together with dierent eector plasmids. Cells were collected 36 h after transfection, and same number of cells (about 1610 6 /well) were lysed and subjected to luciferase assay according to the manufacturer's instructions (Promega). Light emission was evaluated with the aid of a scintillation counter or a luminometer and expressed as counts per min (c.p.m.) or Relative Light Units as indicated. The use of normalization plasmids was avoided due to the ability of B-MYB to functionally interact with viral promoters, with confounding eects. Thus, each experimental point was always performed in triplicate and experiments were repeated at least threefold with dierent plasmid preparations.
